Cytogen to license prostate test technology:
This article was originally published in Clinica
Cytogen plans to obtain an exclusive, worldwide licence to Molecular Staging's Rolling Circle Amplification Technology (RCAT) to develop in vitro tests for prostate specific membrane antigen (PSMA) and prostate specific antigen (PSA). According to Princeton, New Jersey-based Cytogen, serum PSMA is increased in prostate cancer, but appears to be unaffected by other miscellaneous events, unlike PSA. Cytogen plans to use the RCAT technology to develop a PSMA and PSA test for prostate cancer and hopes to have an assay for clinical study by mid-2000.
You may also be interested in...
The Environmental Working Group and Scientific Analytical Institute say inadequate testing of talc-containing personal-care products is to blame for findings of asbestos in cosmetics, including three of 21 powder-based cosmetics SAI analyzed at EWG’s request. They continue to push for updated testing standards that include electron microscopy as a core component.
Can Atlas Biomed unlock Japan's self-care market with its direct-to-consumer DNA and microbiome tests? HBW Insight catches up with the company's co-founder and CEO to discuss this and also how Atlas has been driving its European expansion plans despite coronavirus.
France's ANSES warns women using oral contraceptives not to use a supplement marketed by UK firm Hairburst after linking the product's consumption to two cases of severe acute hepatitis.